Financial Survey: Senesco Technologies (SVON) versus Osiris Therapeutics (OSIR)

Senesco Technologies (OTCMKTS: SVON) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares Senesco Technologies and Osiris Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senesco Technologies N/A -214.14% -85.35%
Osiris Therapeutics N/A N/A N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Senesco Technologies and Osiris Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senesco Technologies 0 0 0 0 N/A
Osiris Therapeutics 0 0 0 0 N/A

Earnings and Valuation

This table compares Senesco Technologies and Osiris Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Senesco Technologies $80,000.00 186.33 -$5.79 million ($0.24) -1.21
Osiris Therapeutics $59.87 million 3.36 -$1.78 million ($0.20) -29.10

Osiris Therapeutics has higher revenue and earnings than Senesco Technologies. Osiris Therapeutics is trading at a lower price-to-earnings ratio than Senesco Technologies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Senesco Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Osiris Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Institutional & Insider Ownership

0.3% of Osiris Therapeutics shares are held by institutional investors. 25.1% of Senesco Technologies shares are held by insiders. Comparatively, 44.6% of Osiris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Osiris Therapeutics beats Senesco Technologies on 7 of the 9 factors compared between the two stocks.

About Senesco Technologies

Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Receive News & Ratings for Senesco Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply